Tag: Ichnos Glenmark Innovation

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)NEW YORK and NORTH CHICAGO, Ill., July 10, 2025...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsIchnos Glenmark Innovation

REGENCELL DEADLINE TUESDAY JUNE 23rd: Bragar Eagel & Squire, P.C. Reminds Regencell Bioscience Holdings Limited (NASDAQ:RGC) Investors They Have Until June 23rd to Contact...

HCI Group Enters the Tokenized Real-World Assets Market with Pilot Project Mirroring Returns of Specific Participations in HCI’s Catastrophe XOL Reinsurance Programs

TTM Technologies, Inc. to Acquire Privately-Held, European-Based Swiss Technology Group AG and ILFA GmbH

Tag: Ichnos Glenmark Innovation

Ichnos Glenmark Innovation (IGI) and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us